

**Antioxidants for preventing and reducing muscle soreness after exercise: a Cochrane systematic review**

RANCHORDAS, Mayur <<http://orcid.org/0000-0001-7995-9115>>, ROGERSON, David <<http://orcid.org/0000-0002-4799-9865>>, SOLTANI, Hora <<http://orcid.org/0000-0001-9611-6777>> and COSTELLO, Joseph T.

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/22032/>

---

This document is the Accepted Version [AM]

**Citation:**

RANCHORDAS, Mayur, ROGERSON, David, SOLTANI, Hora and COSTELLO, Joseph T. (2018). Antioxidants for preventing and reducing muscle soreness after exercise: a Cochrane systematic review. *British Journal of Sports Medicine*. [Article]

---

**Copyright and re-use policy**

See <http://shura.shu.ac.uk/information.html>

**Antioxidants for preventing and reducing muscle soreness after exercise:  
a Cochrane systematic review**

Mayur K Ranchordas<sup>1</sup>, David Rogerson<sup>1</sup>, Hora Soltani<sup>2</sup>, Joseph T Costello<sup>3</sup>

1 - Academy of Sport & Physical Activity, Sheffield Hallam University,  
Sheffield, UK.

2 - Centre for Health and Social Care Research, Sheffield Hallam University,  
Sheffield, UK.

3 - Department of Sport and Exercise Science, University of Portsmouth,  
Portsmouth, UK

[Corresponding author: Dr Mayur K. Ranchordas, Academy of Sport &  
Physical Activity, Faculty of Health & Wellebing, Sheffield Hallam University,  
Sheffield, S10 2BP - m.ranchordas@shu.ac.uk](#)

## **Abstract**

### **Objective**

To determine whether antioxidants supplements and antioxidant-enriched foods can prevent or reduce delayed onset muscle soreness after exercise.

### **Methods**

We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, SPORTDiscus, trial registers, reference lists of articles and conference proceedings up to February 2017

### **Results**

In total, 50 studies were included in this review which included a total of 1089 participants (961 were male and 128 were female) with an age range between 16 and 55 years. All studies used an antioxidant dosage higher than the recommended daily amount. The majority of trials (47) had design features that carried a high risk of bias due to selective reporting and poorly described allocation concealment, potentially limiting the reliability of their findings. We rescaled to a 0 to 10 cm scale in order to quantify the actual difference between groups and we found that the 95% CIs for all five follow-up times were all well below the minimal important difference of 1.4 cm: up to 6 hours (MD -0.52, 95% CI -0.95 to -0.08); at 24 hours (MD -0.17, 95% CI -0.42 to 0.07); at 48 hours (MD -0.41, 95% CI -0.69 to -0.12); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02); and at 96 hours (MD -0.03, 95% CI -0.43 to 0.37). Thus, the effect sizes suggesting less muscle soreness with

antioxidant supplementation were very unlikely to equate to meaningful or important differences in practice.

## **Conclusions**

There is moderate to low-quality evidence that high dose antioxidant supplementation does not result in a clinically relevant reduction of muscle soreness after exercise at up to 6 hours or at 24, 48, 72 and 96 hours after exercise. There is no evidence available on subjective recovery and only limited evidence on the adverse effects of taking antioxidant supplements.

## 1 Introduction

2

3 Delayed onset muscle soreness (DOMS) typically occurs after  
4 strenuous and unaccustomed exercise and physical activity. It is classified  
5 as a grade 1 muscle strain injury and is characterised by localised  
6 tenderness and soreness.<sup>1</sup> Depending on the severity of exercise, DOMS  
7 typically peaks between 24 to 72 hours after a bout of exercise but  
8 eventually disappears after five to seven days.<sup>2-7</sup> DOMS could be  
9 detrimental for athletes who are returning to training from a prolonged  
10 period of inactivity. In addition, DOMS could deter individuals from  
11 adhering to an exercise programme. For some individuals, DOMS could  
12 result from excessive physical activity associated with daily living,  
13 particularly if repeated eccentric movements or unaccustomed physical  
14 activity are involved.

15

16 Several theories have been proposed to explain the mechanisms  
17 underlying DOMS. These include lactate accumulation,<sup>8</sup> inflammation,<sup>9</sup>  
18 muscle spasm,<sup>10</sup> muscle damage,<sup>11</sup> connective tissue damage,<sup>12</sup> and  
19 increased muscle temperature.<sup>13</sup> A common feature of several of these  
20 proposed mechanisms is an increased production of free radicals,<sup>14</sup> and  
21 reactive oxygen species. Indeed, it has been shown that reactive oxygen  
22 species are produced in nearly every biological process and that they also  
23 play a crucial role as signalling molecules for translating the exercise signals  
24 to appropriate adaptations.<sup>15</sup>

25

26 The rationale for taking antioxidant supplements after exercise to  
27 reduce DOMS comes from the notion that they could reduce the negative

28 effects of reactive oxygen species and oxidative stress resulting from  
29 exercise.<sup>16</sup> Oxidative stress could deplete the body's antioxidant defences  
30 and increase the rate of free radical production.<sup>17-19</sup> Moreover,  
31 unaccustomed, eccentric and exhaustive exercise may also induce  
32 inflammatory reactions which can contribute to increased reactive oxygen  
33 species production and reduced antioxidant defences.<sup>20</sup> These can cause  
34 exercise-induced muscle damage and result in DOMS.<sup>1</sup> Dietary antioxidants  
35 may counteract oxidative stress by reducing the production of free radical  
36 and reactive oxygen species associated with exercise.<sup>17</sup> Reducing DOMS  
37 could be beneficial to athletes when returning to training from injury (i.e.  
38 after a period of inactivity), and it could help sedentary and older  
39 individuals recover from unaccustomed physical activity.

40  
41 The ease of taking antioxidant supplements to prevent and reduce  
42 muscle soreness after exercise and enhance recovery makes it an attractive  
43 option for physically active individuals. Moreover, antioxidant supplements  
44 are available to buy from supermarkets and health food stores and some  
45 are marketed to enhance recovery. Despite the popularity of antioxidant  
46 supplements, the evidence supporting its used is mixed.<sup>21-23</sup> Therefore, the  
47 objective of this systematic review was to determine whether antioxidant  
48 supplements and antioxidant-enriched foods could prevent or reduce  
49 DOMS after exercise.

50  
51  
52  
53  
54

55 **Methods**

56

57 **Inclusion criteria**

58

59 Any randomised controlled trials or quasi-randomised controlled  
60 trials investigating the effects of dietary antioxidants on preventing or  
61 reducing delayed onset muscle soreness were considered for this meta-  
62 analysis.

63

64 **Search strategy**

65

66 A systematic search of the literature was conducted in the  
67 Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the  
68 Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE,  
69 Embase and SPORTDiscus, current to February 2017 was performed by two  
70 authors. ClinicalTrials.gov and the World Health Organization Clinical Trials  
71 Registry Platform were also searched for any ongoing or recently  
72 completed studies. Experts in the field were also contacted to find  
73 unpublished trials. The reference list of all included studies and relevant  
74 reviews were also screened for further references to relevant trials. No  
75 language restrictions were applied.

76

77 **Data extraction**

78

79 Two authors independently extracted data using a customised form.  
80 We resolved any disagreements by consultation with the other authors. In

81 some cases, the primary authors of selected studies were contacted for  
82 additional information and data.

### 83 84 **Heterogeneity and risk of bias**

85 For all included studies, methodologic quality was assessed by two  
86 authors independently, using the Cochrane risk of bias tool.<sup>24</sup> We resolved  
87 any disagreement by discussion and, if necessary, consultation with the  
88 other authors. Heterogeneity was assessed using the Chi<sup>2</sup> test and I<sup>2</sup>  
89 statistic, with the level of significance for the Chi<sup>2</sup> test being set at P = 0.1.<sup>25</sup>  
90 We interpreted values of I<sup>2</sup> as follows: might not be important (0% to 40%);  
91 may represent moderate heterogeneity (30% to 60%); may represent  
92 substantial heterogeneity (50% to 90%); and may represent considerable  
93 heterogeneity (75% to 100%).

### 94 95 **Meta-analyses**

96  
97 Mean differences with 95% confidence intervals were calculated  
98 for continuous data using RevMan (Review Manager; RevMan). When  
99 studies used different ways of measuring a continuous outcome  
100 standardised mean differences and 95% confidence intervals were  
101 calculated. Due to substantial clinical and statistically significant  
102 heterogeneity a random-effects model, again with 95% confidence intervals,  
103 was employed.

### 104 105 **Subgroup analyses**

106



107            Subgroup analyses were performed in RevMan. Subgroup analyses  
108 included the timing of anti-oxidant administration (pre-exercise versus  
109 post-exercise), type of exercise (mechanically induced damage versus  
110 whole body aerobic exercise), and funding source (trials funded by food  
111 company or provider of antioxidant supplements versus those not funded  
112 by food company or provider of antioxidant supplements).

113

## 114 Results

### 115 116 Study Characteristics

117  
118 We completed the search in February 2017 and 1558 records from  
119 the following databases were screened: Cochrane Bone, Joint and Muscle  
120 Trauma Group Specialised Register (25 records), CENTRAL (194),MEDLINE  
121 (302), Embase (476), SPORTDiscus (117), ClinicalTrials.gov (162) and the  
122 WHO International Clinical Trials Registry Platform (282). We also identified  
123 12 potentially eligible studies from ongoing searches and through  
124 contacting experts in the field. The search resulted in the identification of  
125 128 potentially eligible studies, for which we obtained full reports. Upon  
126 study selection, we included 50 and excluded 77.

127  
128 The 50 trials included in this systematic review had a total of 1089  
129 participants with 901 participants in the parallel-group trials (range 7 to 54)  
130 and 188 participants in the cross-over trials (range 8 to 24). All 50 studies  
131 were randomised controlled trials; no quasi-randomised controlled trials  
132 met the inclusion criteria. Thirty-eight trials (with a total of 901  
133 participants) employed a parallel design.<sup>21,22,26-59</sup> The other 12 trials (with a  
134 total of 188 participants) employed a cross-over design.<sup>60-71</sup>

135  
136 Seven trials were designed to produce DOMS under field-based  
137 conditions,<sup>22,34,43-45,63</sup> and the other 43 studies were designed to produce  
138 DOMS under laboratory-based conditions. In all trials, an antioxidant  
139 supplement was compared with a placebo. Thirteen trials used antioxidants  
140 from a whole natural food source,<sup>22,28,29,40,43,45,50,61,63,64,67,70,71</sup> 19 used an

141 antioxidant extract or mixed  
142 antioxidants,<sup>26,31,34,36,37,39,41,42,44,47,48,51,52,54,60,65,66,68</sup> and 18 provided either  
143 vitamin C or vitamin E or both together.<sup>21,27,30,32,33,35,38,46,49,53,55,57-59,62,69,72,73</sup>  
144 All studies used a placebo either as a powder, capsule or drink; however,  
145 three studies did not provide details of what the placebo comprised.<sup>46,49,60</sup>  
146 No trials compared high-dose versus low-dose antioxidant supplements,  
147 where the low-dose supplementation is within normal or recommended  
148 levels for the antioxidant involved.

150           There was a large variation across the studies regarding the  
151 duration of supplementation: the shortest period was under one day<sup>68,69</sup>  
152 and the longest period was 91 days.<sup>39</sup> Although the form of supplement  
153 was varied, including capsules, powders and drinks, every study used an  
154 antioxidant dosage higher than the recommended daily amount. Every  
155 study required the participant to ingest the supplement orally either once  
156 daily or up to three times per day. Supplementation was taken before, the  
157 day of and after exercise for up to several days in all the studies except for  
158 three studies where supplements were post-exercise only.<sup>65,67,74</sup>

## 160           **Funding**

161  
162           In all, 21 studies were industry funded either by a food company or  
163 a provider of antioxidant supplements.<sup>26-29,31,32,39,41,43,47,50,52,58,60,61,67-71,73</sup> Of  
164 the 28 other studies reporting on funding, 15 declared “none” in their  
165 report;<sup>21,30,33-36,40,44,46,49,53,57,59,62</sup> the other 13 referring to various sources of  
166 university and public body research funding sources.<sup>22,37,38,42,45,48,51,54,55,63-66</sup>

167 We were unsuccessful in obtaining information on funding from the only  
168 trial that did not report on this.<sup>56</sup>

### 170 Risk of Bias

171 Forty-seven trials (94%) had design features that were deemed to carry a  
172 high risk of bias due to random sequence generation (19 trials),<sup>21,22,27,35,37,41-  
173 43,46,49,52,56,57,60,61,65,66,70,71</sup> selective reporting (41 trials),<sup>21,22,26-33,35-40,42,46-49,51,53-  
174 63,66-73</sup> poorly described allocation concealment (30 trials),<sup>21,22,27,35-  
175 37,40,42,43,45-47,49,51-53,56,58-62,64,65,68-73</sup> attrition bias (12 trials),<sup>32,40,42,45,47,52,54,55,60-  
176 62,65</sup> and lack of dietary monitoring during the intervention (16 trials),  
177 <sup>26,29,31,42,46,49,53-55,57,59,63-66,69</sup> potentially limiting the reliability of their findings.

### 180 Primary Outcomes

181 All of the 50 trials included in this review measured muscle  
182 soreness, however, there were differences in the types of soreness scales  
183 used. Thirty-three trials measured muscle soreness using a 0 to 10 cm (or 0  
184 to 100 mm) visual analogue scale (VAS). Of the 17 other trials, seven<sup>65,75-80</sup>  
185 measured soreness using a 1 to 10 cm scale; four trials<sup>29,45,81,82</sup> used the 0 to  
186 20 cm (or 0 to 200 mm) scale; two studies<sup>38,48</sup> used a 0- to 6-point scale,  
187 Herrlinger<sup>39</sup> used a 0 to 7 Likert scale, Drobnic<sup>36</sup> used a 0- to 4-point scale;  
188 Cobley<sup>34</sup> used a 0 to 12 cm scale and Su<sup>56</sup> used the Borg CR-10 scale. The  
189 Borg CR-10 scale ranges from 0 (no soreness) to 10 (maximal soreness). In  
190 the included studies, participants were asked to rate muscle soreness on  
191 the soreness scales by either carrying out a squat using body weight, self-  
192 palpitation of muscle or based on muscle soreness at rest.

194 Forty-eight studies presented data on muscle soreness at various  
195 different time points based on various visual analogue scale (VAS) scores.  
196 Results are presented at eight follow-up times after exercise: up to 6 hours,  
197 and at 24, 48, 73, 96, 120, 144 and 168 hours.

198  
199 Antioxidant supplementation reduced muscle soreness in  
200 comparison to the placebo condition when measured up to 6 hours post-  
201 exercise (standardised mean difference (SMD) -0.30, 95% confidence  
202 interval (CI) -0.56 to -0.04; participants = 525; studies = 21;  $I^2 = 53\%$ ; low-  
203 quality evidence); at 24 hours after exercise (SMD -0.13, 95% CI -0.27 to  
204 0.00; participants = 936; studies = 41;  $I^2 = 5\%$ ; moderate-quality evidence);  
205 at 48 hours after exercise (SMD -0.24, 95% CI -0.42 to -0.07; participants =  
206 1047; studies = 45;  $I^2 = 47\%$ ; low quality evidence); and at 72 hours after  
207 exercise (SMD -0.19, 95% CI -0.38 to -0.00; participants = 657; studies = 28;  
208  $I^2 = 27\%$ ; moderate-quality evidence). There was little effect of antioxidants  
209 on muscle soreness at 96 hours after exercise (SMD -0.05, 95% CI -0.29 to  
210 0.19; participants = 436; studies = 17;  $I^2 = 31\%$ ; low-quality evidence). Far  
211 fewer trials provided data at five days or subsequently. There was very low-  
212 quality evidence of little effect of antioxidants on muscle soreness at 120  
213 hours (SMD 0.21, 95% CI -0.26 to 0.69; participants = 128; studies = 4;  $I^2 =$   
214  $39\%$ ), at 144 hours (SMD -0.23, 95% CI -1.11 to 0.65; participants = 20;  
215 studies = 1) or at 168 hours (SMD -0.04, 95% CI -0.48 to 0.41; participants =  
216 80; studies = 4;  $I^2 = 0\%$ ).

217  
218 As there was considerable variation in the units used to measure  
219 muscle soreness, we rescaled all trials to the 0 to 10 scale at the first five  
220 time points in order to explore the actual difference between groups on a

221 standard scale. The results are as follows: up to 6 hours (mean difference  
222 (MD) -0.52, 95%CI -0.95 to -0.08; participants = 525; studies = 21;  $I^2 = 66\%$ );  
223 at 24 hours (MD - 0.17, 95% CI -0.42 to 0.07; participants = 936; studies =  
224 41;  $I^2 = 29\%$ ); at 48 hours (MD -0.41, 95% CI -0.69 to - 0.12; participants =  
225 1047; studies = 45;  $I^2 = 64\%$ ); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02;  
226 participants = 657; studies = 28;  $I^2 = 27\%$ ); and at 96 hours (MD-0.03, 95%  
227 CI -0.43 to 0.37; participants = 436; studies = 17;  $I^2 = 51\%$ ). This rescaling  
228 also allows us to examine whether the antioxidant supplement produces a  
229 clinically important difference. For consistency with Bleakley,<sup>4</sup> we  
230 considered 1.4 cm as the minimal important difference (MID) for pain  
231 reduction on a 10 cm visual analogue scale; this was based on an estimated  
232 MID for musculoskeletal conditions of the shoulder by Tashjian.<sup>83</sup> It is  
233 notable that all of the upper limits of the 95% CIs of these five analyses are  
234 lower than this MID and hence all quantitative differences do not appear to  
235 represent person-relevant differences in muscle soreness.

### 236 **Subgroup and sensitivity analyses**

237  
238  
239 We performed only a few subgroup and sensitivity analyses. We  
240 selected the 24 and 48 hours analyses for subgroup analyses given that  
241 these were the categories with the largest number of trials. We did not use  
242 the up to 6 hours time period because of the variation in the timing of  
243 measurement: i.e. some studies measured this outcome immediately after  
244 exercise whereas other studies measured this up to 2 hours or up to 6  
245 hours after exercise. A sensitivity analysis exploring the use of the fixed-  
246 effect model for all eight follow-up times produced similar results to that of  
247 random-effects model. A subgroup analysis could not be performed on

248 timing of administration (i.e. pre-exercise and post-exercise versus post-  
249 exercise only) because there were very few trials (one or two studies  
250 depending on the time of follow-up) in the post-exercise group. We  
251 performed a subgroup analysis on the type of exercise, that is, mechanically  
252 induced versus whole body aerobic exercise for the 24 and 48 hour follow-  
253 up times. There is no evidence of subgroup differences for muscle soreness  
254 for type of exercise at 24 hours ( $\text{Chi}^2 = 0.44$ ,  $\text{df} = 1$ ;  $P = 0.51$ ,  $I^2 = 0\%$ ) or at  
255 48 hours ( $\text{Chi}^2 = 0.88$ ,  $\text{df} = 1$ ;  $P = 0.35$ ,  $I^2 = 0\%$ ). Our second subgroup  
256 analysis was based on source of funding where we compared studies that  
257 were funded by a food company or provider of antioxidant supplements  
258 versus studies that there were not. There is no evidence of subgroup  
259 differences for muscle soreness according to source of funding at 24 hours  
260 ( $\text{Chi}^2 = 0.03$ ,  $\text{df} = 1$ ,  $P = 0.87$ ,  $I^2 = 0\%$ ) or 48 hours ( $\text{Chi}^2 = 0.10$ ,  $\text{df} = 1$ ,  $P =$   
261  $0.875$   $I^2 = 0\%$ ); no information on funding was available for Su.<sup>56</sup>

263 We conducted a sensitivity analysis testing trials at unclear risk of  
264 bias, relating to random sequence generation, allocation concealment or  
265 both, which included 19 trials.<sup>22,26,28-34,38,39,44,48,50,54,55,63,67,68</sup> This analysis  
266 made little difference to the overall effect at either 24 hours post-exercise  
267 (SMD -0.10, 95% CI -0.37 to 0.17; participants = 280; studies = 14;  $I^2 = 19\%$ )  
268 or at 48 hours (SMD -0.31, 95% CI -0.66 to 0.04; participants = 327; studies  
269 = 16;  $I^2 = 57\%$ ).

### 271 **Subjective Recovery**

272 No study measured subjective recovery (return to previous activities  
273 without signs or symptoms).

## Adverse effects

Nine studies<sup>34,41,43-45,50,52,64,65</sup> reporting on a total of 216 participants, reported on this outcome (very low-quality evidence). One study reported that all six participants in the NAC (N-acetylcysteine) supplementation group had diarrhoea, which was mild in five participants and severe diarrhoea in one.<sup>34</sup> The same study reported mild indigestion in four participants (67%) in the NAC group and one of six participants in the placebo group. Another study<sup>43</sup> reported that tart cherry juice caused mild gastrointestinal distress in one of 26 participants taking the antioxidant supplement. Seven studies reported no adverse effects of taking the antioxidant supplementation.<sup>41,44,45,50,52,64,65</sup> The remaining 41 studies failed to report adverse effects.



## 289 Discussion

290 This review examined the effectiveness of antioxidants for  
291 preventing and treating muscle soreness after exercise. Fifty randomised  
292 placebo-controlled studies were included, 12 of which used a crossover  
293 design. The 50 studies involved a total of 1089 participants (961 male; 128  
294 female; age range 16 to 55 years). The studies were heterogeneous,  
295 including the timing (pre-exercise or post exercise), frequency, dose or  
296 duration, and type of antioxidant supplementation, and the type of  
297 preceding delayed onset muscle soreness (DOMS)-producing exercise. All  
298 studies used an antioxidant dosage higher than the recommended daily  
299 amount. No studies compared high-dose versus low-dose, where the low-  
300 dose supplementation was within normal or recommended levels for the  
301 antioxidant involved.

302  
303 Pooled standardised mean difference (SMD) results for muscle  
304 soreness indicated a small difference in favour of antioxidant  
305 supplementation after DOMS-inducing exercise at all main follow ups (up to  
306 6 hours; low-quality evidence, at 24 hours; moderate-quality evidence, at  
307 48 hours; low-quality evidence, at 72 hours; moderate- quality evidence, at  
308 96 hours; low-quality evidence. When, however, we rescaled all the trial  
309 results to the 0 to 10 cm scale in order to compare the actual difference  
310 between groups, we found that the 95% confidence intervals (CIs) for all  
311 five follow up times were all below 1.0 cm, and thus all below the minimal  
312 important difference of 1.4 cm that we used in this review. Thus, all  
313 statistical differences in DOMS favouring antioxidant supplementation were  
314 unlikely to equate to meaningful or important differences in practice.

316           Neither of our subgroup analyses to examine for differences in  
317 effect according to type of DOMS-inducing exercise (mechanical versus  
318 whole body aerobic) or according to funding source confirmed subgroup  
319 differences. Sensitivity analyses to test the selection of the statistical model  
320 for pooling (fixed-effect instead of random effects) and the exclusion of  
321 cross-over studies all showed similar results to the main analyses. None of  
322 the 50 studies reported on subjective recovery (return to previous activities  
323 without signs or symptoms). Only nine studies (216 participants) reported  
324 on adverse effects, with actual events reported in two studies. One study<sup>34</sup>  
325 (12 participants) reported that all six participants in the NAC (N-  
326 acetylcysteine supplementation group had diarrhoea, which was mild in  
327 five participants and severe in one. The same study<sup>34</sup> reported mild  
328 indigestion in four participants (67%) in the NAC group and one of six  
329 participants in the placebo group. It should be noted that NAC  
330 supplementation is usually prescribed and it has been found to cause  
331 uncomfortable side effects including nausea and diarrhoea in other studies.  
332 Another study<sup>43</sup> reported that tart cherry juice caused mild gastrointestinal  
333 distress in one of 26 participants taking the antioxidant supplement. The  
334 other seven studies reported no adverse effects of taking the antioxidant  
335 supplementation; this included 10 participants having NAC  
336 supplementation in one study. Overall, the available evidence for adverse  
337 events is very low-quality.

338  
339           The majority of the 1089 participants included in this review were  
340 male (961; 88.2%) and so arguably the findings of the review are mainly  
341 applicable to males but there is no biological basis for why antioxidants  
342 should have a different effect in the two sexes. These sex differences are

343 typical of what is observed in the athletic recovery literature.<sup>3,4,7</sup> More  
344 noteworthy is that no data from highly-trained elite athletes were included  
345 in the analyses; the data pertaining to nine elite athletes tested in  
346 McCormick<sup>63</sup> were not included in the meta-analyses because the exercise  
347 paradigm was completely different to all the other studies included in this  
348 review. As the majority of the participants were either college students or  
349 relatively young and active, these findings cannot be generalised in the elite  
350 athlete population who have a different physiological and training status.  
351 Some reservations in terms of applicability also apply to older individuals  
352 due to their anatomical and physiological characteristics as there were no  
353 older participants included in this review (age range of participants: 16 to  
354 55 years).

355  
356 We assessed the quality of evidence using the GRADE framework,  
357 which combines considerations of risk of bias, indirectness, inconsistency  
358 (heterogeneity), imprecision and publication bias. We downgraded all  
359 outcomes one level for serious risk of bias, due mainly to selective  
360 reporting bias (the majority of the trials failed to report on adverse effects)  
361 and, to a lesser degree, attrition biases. We did not downgrade for  
362 indirectness in relation to muscle soreness. We downgraded two outcomes  
363 for serious inconsistency reflecting heterogeneity that could not be traced  
364 to the inclusion of just one outlier trial. Pooled evidence did not support  
365 downgrading for imprecision. Our tests for publication bias did not reveal a  
366 serious concern, although all were small studies. Thus, we did not  
367 downgrade for publication bias. We concluded that the quality of the  
368 evidence ranged from moderate to very low.

369

370 It is important to acknowledge some important limitations of this  
371 review. Firstly, data from 14 studies<sup>21,27,35,37,42,47,52,56,60,61,65,67,70,71</sup> were  
372 extracted from graphs using Graphclick 2010 Arizona (version 3.0.2, 2010)  
373 because the authors did not respond to several emails requested mean and  
374 SD data. Whilst this is not ideal, we tried to minimise error by having two  
375 review authors (MR and DR) independently extract the data, with any  
376 discrepancies resolved by consultation with the third and fourth authors  
377 (HS and JC). Secondly, our inclusion of cross-over studies and our analysis of  
378 their data as if from a parallel group trial, thus without adjustment for the  
379 cross-over design, are other potential sources of bias. With one exception,  
380 the cross-over studies included in this review used a washout period of two  
381 to six weeks, which is sufficient to allow the muscles to recover. The  
382 exception<sup>60</sup> used a washout period of only five days between treatments  
383 and therefore carries some risk of a carry-over effect; sensitivity analysis to  
384 check on the effect of excluding the data from this trial did not result in  
385 important changes. Further sensitivity analyses checking the effects of  
386 excluding the cross-over trials from the muscle soreness analyses showed  
387 that our inclusion and handling of the cross-over studies did not have an  
388 important impact on the review results.

## 391 **Conclusions**

393 There is moderate- to low-quality evidence that antioxidant  
394 supplementation does not result in a clinically relevant reduction of DOMS  
395 after exercise at any of the five follow-up times assessed (up to 6 hours and  
396 at 24, 48, 72 and 96 hours after exercise. There is no evidence available on

397 subjective recovery and only limited evidence on adverse effects of taking  
398 antioxidant supplements. Some antioxidant supplements such as N-  
399 acetylcysteine may cause unwanted side effects including gastrointestinal  
400 discomfort and diarrhoea. Thus, taking antioxidants supplements and  
401 antioxidant-enriched foods is not an effective strategy to reduce DOMS  
402 after exercise.

403

#### What is already known?

Taking antioxidants supplements to reduce muscle soreness is a common strategy used by recreational and elite athletes. However, little is known about how effective antioxidants are at reducing delayed onset muscle soreness.

#### What are the new findings?

- There is moderate to low-quality evidence that high dose antioxidant supplementation does not result in a clinically relevant reduction of muscle soreness after exercise at up to 6 hours or at 24, 48, 72 and 96 hours after exercise.
- There is no evidence available on subjective recovery and only limited evidence on the adverse effects of taking antioxidant supplements.
- The findings of, and messages from, this review provide an opportunity for researchers and other stakeholders to come together and consider what are the priorities, and underlying justifications, for future research in this area.

404

405

406

407

408 References

- 409 1. Cheung K, Hume PA, Maxwell L. Delayed onset muscle soreness. *Sports*  
410 *Medicine*. 2003;33(2):145-164.
- 411 2. Armstrong R. Mechanisms of exercise-induced delayed onset muscular  
412 soreness: A brief review. *Med Sci Sports Exerc*. 1984;16(6):529-538.
- 413 3. Bieuzen F, Bleakley CM, Costello JT. Contrast water therapy and exercise  
414 induced muscle damage: A systematic review and meta-analysis. *PLoS One*.  
415 2013;8(4):e62356.
- 416 4. Bleakley C, McDonough S, Gardner E, et al. Cold-water immersion  
417 (cryotherapy) for preventing and treating muscle soreness after exercise.  
418 *Sao Paulo medical journal*. 2012;130(5):348-348.
- 419 5. Byrnes W, Clarkson P. Delayed onset muscle soreness and training. *Clin*  
420 *Sports Med*. 1986;5(3):605-614.
- 421 6. Cleak M, Eston R. Delayed onset muscle soreness: Mechanisms and  
422 management. *J Sports Sci*. 1992;10(4):325-341.
- 423 7. Costello JT, Baker PR, Minett GM, Bieuzen F, Stewart IB, Bleakley C.  
424 Whole-body cryotherapy (extreme cold air exposure) for preventing and

- 425 treating muscle soreness after exercise in adults. *The Cochrane Library*.  
426 2015.
- 427 8. Asmussen E. Positive and negative muscular work. *Acta Physiol Scand*.  
428 1953;28(4):364-382.
- 429 9. Smith LL. Acute inflammation: The underlying mechanism in delayed  
430 onset muscle soreness? *Med Sci Sports Exerc*. 1991;23(5):542-551.
- 431 10. De Vries HA. Quantitative electromyographic investigation of the spasm  
432 theory of muscle pain. *Ins.Counsel J*. 1967;34:455.
- 433 11. Hough T. Ergographic studies in muscular fatigue and soreness. *J Boston*  
434 *Soc Med Sci*. 1900;5(3):81-92.
- 435 12. Weinstock C, König D, Harnischmacher R, Keul J, Berg A, Northoff H.  
436 Effect of exhaustive exercise stress on the cytokine response. *Med Sci*  
437 *Sports Exerc*. 1997;29(3):345-354.
- 438 13. Davies C, BAKNES C. Negative (eccentric) work. II. physiological  
439 responses to walking uphill and downhill on a motor-driven treadmill.  
440 *Ergonomics*. 1972;15(2):121-131.



- 441 14. Maughan RJ, Donnelly AE, Gleeson M, Whiting PH, Walker KA, Clough PJ.  
442 Delayed-onset muscle damage and lipid peroxidation in man after a  
443 downhill run. *Muscle Nerve*. 1989;12(4):332-336.
- 444 15. Margaritelis NV, Cobley JN, Paschalis V, et al. Principles for integrating  
445 reactive species into in vivo biological processes: Examples from exercise  
446 physiology. *Cell Signal*. 2016;28(4):256-271.
- 447 16. Close GL, Ashton T, McArdle A, Maclaren DP. The emerging role of free  
448 radicals in delayed onset muscle soreness and contraction-induced muscle  
449 injury. *Comparative Biochemistry and Physiology Part A: Molecular &*  
450 *Integrative Physiology*. 2005;142(3):257-266.
- 451 17. Powers SK, Jackson MJ. Exercise-induced oxidative stress: Cellular  
452 mechanisms and impact on muscle force production. *Physiol Rev*.  
453 2008;88(4):1243-1276.
- 454 18. Ramel A, Wagner K, Elmadfa I. Plasma antioxidants and lipid oxidation  
455 after submaximal resistance exercise in men. *Eur J Nutr*. 2004;43(1):2-6.

- 456 19. Witt EH, Reznick AZ, Viguie CA, Starke-Reed P, Packer L. Exercise,  
457 oxidative damage and effects of antioxidant manipulation. *J Nutr.*  
458 1992;122(suppl\_3):766-773.
- 459 20. Tsai K, Hsu T, Hsu K, et al. Oxidative DNA damage in human peripheral  
460 leukocytes induced by massive aerobic exercise. *Free Radical Biology and*  
461 *Medicine.* 2001;31(11):1465-1472.
- 462 21. Bryer S, Goldfarb AH. Effect of high dose vitamin C supplementation on  
463 muscle soreness, damage, function, and oxidative stress to eccentric  
464 exercise. *Int J Sport Nutr Exerc Metab.* 2006;16(3):270-280.
- 465 22. Howatson G, McHugh M, Hill J, et al. Influence of tart cherry juice on  
466 indices of recovery following marathon running. *Scand J Med Sci Sports.*  
467 2010;20(6):843-852.
- 468 23. Mastaloudis A, Traber MG, Carstensen K, Widrick JJ. Antioxidants did  
469 not prevent muscle damage in response to an ultramarathon run. *Med Sci*  
470 *Sports Exerc.* 2006;38(1):72-80.

- 471 24. Higgins J, Altman DG. Assessing risk of bias in included studies.  
472 *Cochrane handbook for systematic reviews of interventions: Cochrane book*  
473 *series*. 2008:187-241.
- 474 25. Deeks JJ, Higgins J, Altman DG. Analysing data and undertaking meta-  
475 analyses. *Cochrane handbook for systematic reviews of interventions:*  
476 *Cochrane book series*. 2008:243-296.
- 477 26. Bailey DM, Williams C, Betts JA, Thompson D, Hurst TL. Oxidative stress,  
478 inflammation and recovery of muscle function after damaging exercise:  
479 Effect of 6-week mixed antioxidant supplementation. *Eur J Appl Physiol*.  
480 2011;111(6):925-936.
- 481 27. Beaton LJ, Allan DA, Tarnopolsky MA, Tiidus PM, Phillips SM.  
482 Contraction-induced muscle damage is unaffected by vitamin E  
483 supplementation. *Med Sci Sports Exerc*. 2002;34(5):798-805.
- 484 28. Bell PG, Walshe IH, Davison GW, Stevenson EJ, Howatson G. Recovery  
485 facilitation with montmorency cherries following high-intensity,  
486 metabolically challenging exercise. *Applied Physiology, Nutrition, and*  
487 *Metabolism*. 2014;40(4):414-423.

- 488 29. Bell PG, Stevenson E, Davison GW, Howatson G. The effects of  
489 montmorency tart cherry concentrate supplementation on recovery  
490 following prolonged, intermittent exercise. *Nutrients*. 2016;8(7):441.
- 491 30. Bloomer RJ. Effects of antioxidant therapy in women exposed to  
492 eccentric exercise. *Int J Sport Nutr Exerc Metab*. 2004;14(4):377-388.
- 493 31. Bloomer RJ, Fry A, Schilling B, Chiu L, Hori N, Weiss L. Astaxanthin  
494 supplementation does not attenuate muscle injury following eccentric  
495 exercise in resistance-trained men. *Int J Sport Nutr Exerc Metab*.  
496 2005;15(4):401-412.
- 497 32. Bloomer RJ, Falvo MJ, Schilling BK, Smith WA. Prior exercise and  
498 antioxidant supplementation: Effect on oxidative stress and muscle injury.  
499 *Journal of the International Society of Sports Nutrition*. 2007;4(1):9.
- 500 33. Close GL, Ashton T, Cable T, et al. Ascorbic acid supplementation does  
501 not attenuate post-exercise muscle soreness following muscle-damaging  
502 exercise but may delay the recovery process. *Br J Nutr*. 2006;95(5):976-981.
- 503 34. Cobley JN, McGlory C, Morton JP, Close GL. N-acetylcysteine's  
504 attenuation of fatigue after repeated bouts of intermittent exercise:

- 505 Practical implications for tournament situations. *Int J Sport Nutr Exerc*  
506 *Metab.* 2011;21(6):451-461.
- 507 35. Connolly D, Lauzon C, Agnew J, Dunn M, Reed B. The effects of vitamin  
508 C supplementation on symptoms of delayed onset muscle soreness. *J*  
509 *Sports Med Phys Fitness.* 2006;46(3):462.
- 510 36. Drobic F, Riera J, Appendino G, et al. Reduction of delayed onset  
511 muscle soreness by a novel curcumin delivery system (meriva®): A  
512 randomised, placebo-controlled trial. *Journal of the International Society of*  
513 *Sports Nutrition.* 2014;11(1):31.
- 514 37. Goldfarb AH, Garten RS, Cho C, Chee PD, Chambers LA. Effects of a  
515 fruit/berry/vegetable supplement on muscle function and oxidative stress.  
516 *Med Sci Sports Exerc.* 2011;43(3):501-508.
- 517 38. He F, Hockemeyer J, Sedlock D. Does combined antioxidant vitamin  
518 supplementation blunt repeated bout effect? *Int J Sports Med.*  
519 2015;36(05):407-413.

- 520 39. Herrlinger KA, Chirouzes DM, Ceddia MA. Supplementation with a  
521 polyphenolic blend improves post-exercise strength recovery and muscle  
522 soreness. *Food & nutrition research*. 2015;59(1):30034.
- 523 40. Hutchison AT, Flieller EB, Dillon KJ, Leverett BD. Black currant nectar  
524 reduces muscle damage and inflammation following a bout of high-  
525 intensity eccentric contractions. *Journal of dietary supplements*.  
526 2016;13(1):1-15.
- 527 41. Kerksick CM, Kreider RB, Willoughby DS. Intramuscular adaptations to  
528 eccentric exercise and antioxidant supplementation. *Amino Acids*.  
529 2010;39(1):219-232.
- 530 42. Krotkiewski M, Brzezinska Z, Liu B, Grimby G, Palm S. Prevention of  
531 muscle soreness by pretreatment with antioxidants. *Scand J Med Sci Sports*.  
532 1994;4(3):191-199.
- 533 43. Kuehl KS, Perrier ET, Elliot DL, Chesnutt JC. Efficacy of tart cherry juice in  
534 reducing muscle pain during running: A randomized controlled trial. *Journal*  
535 *of the International Society of Sports Nutrition*. 2010;7(1):17.

536 44. Laupheimer MW, Perry M, Benton S, Malliaras P, Maffulli N. Resveratrol  
537 exerts no effect on inflammatory response and delayed onset muscle  
538 soreness after a marathon in male athletes.: A randomised, double-blind,  
539 placebo-controlled pilot feasibility study. *Transl Med UniSa*. 2014;10:38-42.

540 45. Lynn A, Garner S, Nelson N, Simper T, Hall A, Ranchordas M. Effect of  
541 bilberry juice on muscle damage and inflammation in runners completing a  
542 half marathon. *Proc Nutr Soc*. 2015;74(OCE5).

543 46. McBRIDE JM, Kraemer WJ, Triplett-McBride T, Sebastianelli W. Effect of  
544 resistance exercise on free radical production. *Med Sci Sports Exerc*.  
545 1998;30(1):67-72.

546 47. McFarlin BK, Venable AS, Henning AL, et al. Reduced inflammatory and  
547 muscle damage biomarkers following oral supplementation with  
548 bioavailable curcumin. *BBA clinical*. 2016;5:72-78.

549 48. Meamarbashi A, Abedini F. Preventive effects of purslane extract on  
550 delayed onset muscle soreness induced by one session bench-stepping  
551 exercise. *Isokinetics Exerc Sci*. 2011;19(3):199-206.

- 552 49. Nie J, Lin H. Effects of vitamin C supplementation on recovery from  
553 eccentric exercise-induced muscle soreness and damage in junior athletes.  
554 *J Exerc Sci Fit.* 2004;2(2):94-98.
- 555 50. O'Connor PJ, Carvalho AL, Freese EC, Cureton KJ. Grape consumption's  
556 effects on fitness, muscle injury, mood, and perceived health. *Int J Sport*  
557 *Nutr Exerc Metab.* 2013;23(1):57-64.
- 558 51. O'Fallon KS, Kaushik D, Michniak-Kohn B, Dunne CP, Zambraski EJ,  
559 Clarkson PM. Effects of quercetin supplementation on markers of muscle  
560 damage and inflammation after eccentric exercise. *Int J Sport Nutr Exerc*  
561 *Metab.* 2012;22(6):430-437.
- 562 52. Phillips T, Childs AC, Dreon DM, Phinney S, Leeuwenburgh C. A dietary  
563 supplement attenuates IL-6 and CRP after eccentric exercise in untrained  
564 males. *Med Sci Sports Exerc.* 2003;35(12):2032-2037.
- 565 53. Shafat A, Butler P, Jensen R, Donnelly A. Effects of dietary  
566 supplementation with vitamins C and E on muscle function during and after  
567 eccentric contractions in humans. *Eur J Appl Physiol.* 2004;93(1-2):196-202.



- 568 54. Silva LA, Silveira PC, Pinho CA, Tuon T, Pizzol FD, Pinho RA. N-  
569 acetylcysteine supplementation and oxidative damage and inflammatory  
570 response after eccentric exercise. *Int J Sport Nutr Exerc Metab.*  
571 2008;18(4):379-388.
- 572 55. Silva LA, Pinho CA, Silveira PC, et al. Vitamin E supplementation  
573 decreases muscular and oxidative damage but not inflammatory response  
574 induced by eccentric contraction. *The Journal of Physiological Sciences.*  
575 2010;60(1):51.
- 576 56. Su Q, Tian Y, Zhang J, Zhang H. Effects of allicin supplementation on  
577 plasma markers of exercise-induced muscle damage, IL-6 and antioxidant  
578 capacity. *Eur J Appl Physiol.* 2008;103(3):275.
- 579 57. Theodorou AA, Nikolaidis MG, Paschalis V, et al. No effect of antioxidant  
580 supplementation on muscle performance and blood redox status  
581 adaptations to eccentric training—. *Am J Clin Nutr.* 2011;93(6):1373-1383.
- 582 58. Thompson D, Williams C, McGregor SJ, et al. Prolonged vitamin C  
583 supplementation and recovery from demanding exercise. *Int J Sport Nutr*  
584 *Exerc Metab.* 2001;11(4):466-481.

- 585 59. Thompson D, Bailey D, Hill J, Hurst T, Powell J, Williams C. Prolonged  
586 vitamin C supplementation and recovery from eccentric exercise. *Eur J Appl*  
587 *Physiol.* 2004;92(1-2):133-138.
- 588 60. Arent SM, Senso M, Golem DL, McKeever KH. The effects of theaflavin-  
589 enriched black tea extract on muscle soreness, oxidative stress,  
590 inflammation, and endocrine responses to acute anaerobic interval  
591 training: A randomized, double-blind, crossover study. *Journal of the*  
592 *International Society of Sports Nutrition.* 2010;7(1):11.
- 593 61. Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP.  
594 Efficacy of a tart cherry juice blend in preventing the symptoms of muscle  
595 damage. *Br J Sports Med.* 2006;40(8):679-83; discussion 683.
- 596 62. Kaminski M, Boal R. An effect of ascorbic acid on delayed-onset muscle  
597 soreness. *Pain.* 1992;50(3):317-321.
- 598 63. McCormick R, Peeling P, Binnie M, Dawson B, Sim M. Effect of tart  
599 cherry juice on recovery and next day performance in well-trained water  
600 polo players. *Journal of the International Society of Sports Nutrition.*  
601 2016;13(1):41.

- 602 64. McLeay Y, Barnes MJ, Mundel T, Hurst SM, Hurst RD, Stannard SR.  
603 Effect of new zealand blueberry consumption on recovery from eccentric  
604 exercise-induced muscle damage. *Journal of the International Society of*  
605 *Sports Nutrition*. 2012;9(1):19.
- 606 65. Michailidis Y, Karagounis LG, Terzis G, et al. Thiol-based antioxidant  
607 supplementation alters human skeletal muscle signaling and attenuates its  
608 inflammatory response and recovery after intense eccentric exercise—. *Am J*  
609 *Clin Nutr*. 2013;98(1):233-245.
- 610 66. Nicol LM, Rowlands DS, Fazakerly R, Kellett J. Curcumin  
611 supplementation likely attenuates delayed onset muscle soreness (DOMS).  
612 *Eur J Appl Physiol*. 2015;115(8):1769-1777.
- 613 67. Peschek K, Pritchett R, Bergman E, Pritchett K. The effects of acute post  
614 exercise consumption of two cocoa-based beverages with varying flavanol  
615 content on indices of muscle recovery following downhill treadmill running.  
616 *Nutrients*. 2013;6(1):50-62.
- 617 68. Tanabe Y, Maeda S, Akazawa N, et al. Attenuation of indirect markers of  
618 eccentric exercise-induced muscle damage by curcumin. *Eur J Appl Physiol*.  
619 2015;115(9):1949-1957.

- 620 69. Thompson D, Williams C, Kingsley M, et al. Muscle soreness and  
621 damage parameters after prolonged intermittent shuttle-running following  
622 acute vitamin C supplementation. *Int J Sports Med.* 2001;22(01):68-75.
- 623 70. Trombold JR, Barnes JN, Critchley L, Coyle EF. Ellagitannin consumption  
624 improves strength recovery 2–3 d after eccentric exercise. *Med Sci Sports  
625 Exerc.* 2010;42(3):493-498.
- 626 71. Trombold JR, Reinfeld AS, Casler JR, Coyle EF. The effect of  
627 pomegranate juice supplementation on strength and soreness after  
628 eccentric exercise. *J Strength Cond Res.* 2011;25(7):1782-1788.
- 629 72. Avery NG, Kaiser JL, Sharman MJ, et al. Effects of vitamin E  
630 supplementation on recovery from repeated bouts of resistance exercise. *J  
631 Strength Cond Res.* 2003;17(4):801-809.
- 632 73. Thompson D, Williams C, Garcia-Roves P, McGregor S, McArdle F,  
633 Jackson M. Post-exercise vitamin C supplementation and recovery from  
634 demanding exercise. *Eur J Appl Physiol.* 2003;89(3-4):393-400.

- 635 74. Thompson D, Williams C, Garcia-Roves P, McGregor SJ, McArdle F,  
636 Jackson MJ. Post-exercise vitamin C supplementation and recovery from  
637 demanding exercise. *Eur J Appl Physiol*. 2003;89(3-4):393-400.
- 638 75. Bryer SC, Goldfarb AH. Effect of high dose vitamin C supplementation  
639 on muscle soreness, damage, function, and oxidative stress to eccentric  
640 exercise. *Int J Sport Nutr Exerc Metab*. 2006;16(3):270-280.
- 641 76. Bailey DM, Williams C, Betts JA, Thompson D, Hurst TL. Oxidative stress,  
642 inflammation and recovery of muscle function after damaging exercise:  
643 Effect of 6-week mixed antioxidant supplementation. *Eur J Appl Physiol*.  
644 2011;111(6):925-936.
- 645 77. Goldfarb AH, Garten RS, Cho C, Chee PD, Chambers LA. Effects of a  
646 fruit/berry/vegetable supplement on muscle function and oxidative stress.  
647 *Med Sci Sports Exerc*. 2011;43(3):501-508.
- 648 78. Kaminski M, Boal R. An effect of ascorbic acid on delayed-onset muscle  
649 soreness. *Pain*. 1992;50(3):317-321.

- 650 79. Thompson D, Williams C, Kingsley M, et al. Muscle soreness and  
651 damage parameters after prolonged intermittent shuttle-running following  
652 acute vitamin C supplementation. *Int J Sports Med.* 2001;22(1):68-75.
- 653 80. Thompson D, Williams C, Garcia-Roves P, McGregor SJ, McArdle F,  
654 Jackson MJ. Post-exercise vitamin C supplementation and recovery from  
655 demanding exercise. *Eur J Appl Physiol.* 2003;89(3-4):393-400.
- 656 81. Bell PG, Stevenson E, Davison GW, Howatson G. The effects of  
657 montmorency tart cherry concentrate supplementation on recovery  
658 following prolonged, intermittent exercise. *Nutrients.* 2016;8(7):441.
- 659 82. Howatson G, Milak A. Exercise-induced muscle damage following a bout  
660 of sport specific repeated sprints. *J Strength Cond Res.* 2009;23(8):2419-  
661 2424.
- 662 83. Tashjian RZ, Deloach J, Porucznik CA, Powell AP. Minimal clinically  
663 important differences (MCID) and patient acceptable symptomatic state  
664 (PASS) for visual analog scales (VAS) measuring pain in patients treated for  
665 rotator cuff disease. *J Shoulder Elbow Surg.* 2009;18(6):927-932.
- 666

667 Contributorship

668 Mayur Ranchordas identified the research idea for the review, wrote the  
669 protocol, extracted the data, wrote the review and is the  
670 guarantor.

671 David Rogerson assisted with drafting the protocol and data extraction.

672 Hora Soltani provided feedback on the draft protocol and review.

673 Joseph Costello assisted with data analysis and drafted the final review.

674

675 Funding

676 This research received no funding

677

678 Competing Intrests

679 Mayur Ranchordas co-authored one of the included studies (Lynn 2015).

680 Decisions on inclusion of this study, the 'Risk of bias'

681 assessment and data extraction were undertaken by other review authors

682 (JC, DR), who had no involvement in the study.

683 David Rogerson: none known.

684 Hora Soltani: none known.

685 Joseph Costello: none known.

686

687